Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q3 2023 · 10-Q
Revenue—
Net Income-$6.33M-$6.33MN/M vs Q3 2022 EPS Diluted-$22.16-$22.16N/M vs Q3 2022 Operating Income-$6,561,000N/M Operating Cash Flowderived-$6,240,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end